Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Treatments: Drug: EMEND

Study type: Observational

Funder types: Industry

Identifiers

NCT01074255

MK-0869-184 (Other Identifier)

0869-184

Details and patient eligibility

About

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.

Enrollment: 3,546 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who are treated with EMEND for the first time as per the EMEND label

Exclusion criteria

• Contraindication to EMEND

Trial design

3,546 participants in 1 patient group

Korean Participants Treated With EMEND (aprepitant)

Description:

Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.

Treatment:

Drug: EMEND